RhumbLine Advisers
BLRX

RhumbLine Advisers’s BioLineRX BLRX Stock Holding History

RhumbLine Advisers’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.68K Buy
2,478
+125
+5% +$362 ﹤0.01% 3931
2026
Q1 		$5.43K Sell
2,353
-1,000
-30% -$2.81K ﹤0.01% 3872
2025
Q4 		$9.55K Buy
3,353
+283
+9% +$978 ﹤0.01% 3858
2025
Q3 		$11.6K Sell
3,070
-1,205
-28% -$4.83K ﹤0.01% 3839
2025
Q2 		$19.5K Buy
4,275
+2,745
+179% +$10.1K ﹤0.01% 3797
2025
Q1 		$4.52K Buy
1,530
+456
+42% +$1.84K ﹤0.01% 3918
2024
Q4 		$9.14K Buy
1,074
+259
+32% +$3.82K ﹤0.01% 3894
2024
Q3 		$17.5K Buy
815
+171
+27% +$4.7K ﹤0.01% 3829
2024
Q2 		$14.6K Buy
644
+186
+41% +$4.99K ﹤0.01% 3918
2024
Q1 		$20.5K Sell
458
-12
-3% -$602 ﹤0.01% 3757
2023
Q4 		$29.5K Buy
470
+86
+22% +$5.32K ﹤0.01% 3718
2023
Q3 		$27.9K Buy
384
+44
+13% +$2.96K ﹤0.01% 3732
2023
Q2 		$21.7K Buy
+340
New +$18.8K ﹤0.01% 3803
2022
Q4 		– Sell
-427
Closed -$16K – 3005
2022
Q3 		$16K Buy
427
+63
+17% +$3.59K ﹤0.01% 3069
2022
Q2 		$19K Hold
364
– – ﹤0.01% 3080
2022
Q1 		$25K Hold
364
– – ﹤0.01% 2999
2021
Q4 		$30K Hold
364
– – ﹤0.01% 2996
2021
Q3 		$40K Buy
364
+22
+6% +$2.61K ﹤0.01% 3026
2021
Q2 		$38K Hold
342
– – ﹤0.01% 2978
2021
Q1 		$38K Sell
342
-13
-4% -$1.56K ﹤0.01% 2980
2020
Q4 		$36K Buy
+355
New +$31K ﹤0.01% 3029
2019
Q3 		– Sell
-21
Closed -$5K – 2950
2019
Q2 		$5K Hold
21
– – ﹤0.01% 2965
2019
Q1 		$5K Sell
21
-10
-32% -$2.91K ﹤0.01% 2940
2018
Q4 		$8K Hold
31
– – ﹤0.01% 2973
2018
Q3 		$20K Buy
+31
New +$17.1K ﹤0.01% 2917

Other funds holding BLRX

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
BCV
Banque Cantonale Vaudoise Lausanne, Switzerland $722M AUM 30.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

RhumbLine Advisers's BLRX Position: Q2 2026 in Review

RhumbLine Advisers increased its BioLineRX (BLRX) stake by 5.3% in Q2 2026, buying an estimated $362 and bringing the position to 2,478 shares worth $7.68K. The position accounts for ﹤0.01% of the portfolio, ranked #3931.

RhumbLine Advisers first reported a position in BLRX in Q3 2018 and has held it in 25 quarters since. The position peaked at $40K in Q3 2021. 9 funds tracked by Wall St. Rank hold BLRX as of Q2 2026.

  • RhumbLine Advisers held 2,478 shares of BioLineRX worth $7.68K as of Q2 2026.
  • RhumbLine Advisers bought 125 BioLineRX shares in Q2 2026, an estimated $362.
  • BioLineRX made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3931 holding.
  • RhumbLine Advisers first reported a position in BioLineRX in Q3 2018 and has held it in 25 quarters since.
  • RhumbLine Advisers's BioLineRX position peaked at $40K in Q3 2021.
  • 9 funds tracked by Wall St. Rank held BioLineRX as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.